预防性盆腔照射在中危前列腺癌中的获益:多中心回顾性研究
中位随访77个月,两组无复发生存和总生存无显著差异,但全盆腔放疗组≥3级晚期胃肠道毒性更高。
要点
- 全盆腔放疗未改善中危前列腺癌患者无复发生存或总生存。
- 全盆腔放疗与≥3级晚期胃肠道毒性风险升高相关。
- 两组≥2级急性或晚期毒性发生率相似。
核心结论
- 在中危前列腺癌中,全盆腔放疗相比单纯前列腺放疗未改善无复发生存或总生存,但与严重胃肠道毒性风险增加相关。
主要发现
- 中位随访77个月,单因素分析显示全盆腔放疗与无复发生存无显著关联(HR 0.61;95%CI 0.26-1.42;p=0.25)。
- 多因素分析校正临床和治疗因素后结果相似(HR 0.70;95%CI 0.27-1.81;p=0.46)。
- 总生存结果亦相当。
- ≥2级急性或晚期毒性发生率相似,但全盆腔放疗组≥3级晚期胃肠道毒性更高(14.3% vs 5.4%;p=0.045;OR 2.90)。
关键数值与推荐
- 全盆腔放疗组≥3级晚期胃肠道毒性发生率为14.3%,单纯前列腺放疗组为5.4%(p=0.045;OR 2.90)。
临床怎么用
- 中危前列腺癌患者选择全盆腔放疗需权衡严重胃肠道毒性风险,该研究未显示生存获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Context.Prostate cancer (PCa) is the most common urologic malignancy in men, with most cases diagnosed at a localized stage. The benefit of whole-pelvic radiotherapy (WPRT) to eradicate subclinical nodal disease remains debated, particularly in intermediate-risk PCa. This study assessed the impact of WPRT in this population. METHODS: We conducted a multicenter retrospective study within the AP-HP GRRAP program across five radiotherapy departments. Biopsy-proven intermediate-risk PCa (d'Amico classification) treated with conformational external beam radiotherapy between 2010 and 2019 were included. The primary endpoint was recurrence-free survival (RFS), defined as time from diagnosis to biochemical, local, metastatic recurrence, or death. Secondary endpoints were overall survival (OS) and acute (<6 months) or late (≥6 months) genitourinary (GU), gastrointestinal (GI), and sexual toxicities (CTCAE v4.03/v5.0). Survival outcomes were assessed using univariate and multivariate Cox models. RESULTS: Three hundred patients (60 per center) were included; 94 % received IMRT and 6 % 3D-RT. After a median follow-up of 77 months, univariate analysis showed no significant association between WPRT and RFS (HR; 0.61; 95 % CI, 0.26-1.42; p = 0.25). Multivariable analysis adjusted for clinical and treatment factors yielded similar results (HR, 0.70; 95 % CI, 0.27 to 1.81; p = 0.46). OS results were also comparable. Rates of grade 2 acute or late toxicities were similar, but grade ≥ 3 late GI toxicity was higher with WPRT (14.3 % vs. 5.4 %; p = 0.045; OR 2.90). CONCLUSION: In intermediate-risk PCa, WPRT did not improve RFS or OS compared with prostate-only RT but was associated with an increased risk of severe GI toxicity.
引用
- Raynaud C, Nebbache R, Belkacemi Y, et al. Benefit of prophylactic pelvic irradiation in intermediate-risk prostate cancer: A multicenter retrospective study (iPPAPI). Clin Transl Radiat Oncol. 2025. PMID: 41467108. doi:10.1016/j.ctro.2025.101093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。